The SMaRT plant (Sumitomo Dainippon Manufacturing Plant for Regenerative Medicine & Cell Therapy is claimed to be the world’s first commercial facility dedicated to regenerative and cellular medicine derived from iPS cells and has 2 floors above ground and a total floor area of ​​2,915 m2. At present, the focus is on age-related macular degeneration, Parkinson’s disease, retinal pigment degeneration, spinal cord injury etc, and will conduct investigational drug manufacturing and early commercial production

Dainippon Sumitomo news release, March 1, 2018